 Home > Medical News > Medicines Company News > Hutchison Whampoa Sofantinib's new indication will be approved soon

Hutchison Whampoa Sofantinib's new indication will be approved soon

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

late stage

stage pancreatic cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 7th, Hutchison Whampoa Sofantinib's new indication for the market entered the approval stage and is expected to be approved in the near future
.

According to Hutchison Whampoa’s announcement, the indication is advanced pancreatic neuroendocrine tumor

On December 30 last year, Sofantinib was just approved for marketing for late-stage well-differentiated neuroendocrine tumors of non-pancreatic origin

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.